187 related articles for article (PubMed ID: 37212969)
1. IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis.
Nakasu S; Deguchi S; Nakasu Y
Brain Tumor Pathol; 2023 Jul; 40(3):143-157. PubMed ID: 37212969
[TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation and its interaction with IDH mutations in glioma: Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data.
Vuong HG; Altibi AMA; Duong UNP; Ngo HTT; Pham TQ; Chan AK; Park CK; Fung KM; Hassell L
Crit Rev Oncol Hematol; 2017 Dec; 120():1-9. PubMed ID: 29198322
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma.
Ma S; Rudra S; Campian JL; Dahiya S; Dunn GP; Johanns T; Goldstein M; Kim AH; Huang J
Neurooncol Adv; 2020; 2(1):vdaa126. PubMed ID: 33235995
[TBL] [Abstract][Full Text] [Related]
5. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
6. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
7. TERT promoter mutations contribute to IDH mutations in predicting differential responses to adjuvant therapies in WHO grade II and III diffuse gliomas.
Zhang ZY; Chan AK; Ding XJ; Qin ZY; Hong CS; Chen LC; Zhang X; Zhao FP; Wang Y; Wang Y; Zhou LF; Zhuang Z; Ng HK; Yan H; Yao Y; Mao Y
Oncotarget; 2015 Sep; 6(28):24871-83. PubMed ID: 26314843
[TBL] [Abstract][Full Text] [Related]
8. Relevance of calcification and contrast enhancement pattern for molecular diagnosis and survival prediction of gliomas based on the 2016 World Health Organization Classification.
Michiwaki Y; Hata N; Mizoguchi M; Hiwatashi A; Kuga D; Hatae R; Akagi Y; Amemiya T; Fujioka Y; Togao O; Suzuki SO; Yoshimoto K; Iwaki T; Iihara K
Clin Neurol Neurosurg; 2019 Dec; 187():105556. PubMed ID: 31639630
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and radiological features of glioblastoma, IDH-wildtype, grade 4 with histologically lower-grade gliomas.
Motomura K; Kibe Y; Ohka F; Aoki K; Yamaguchi J; Saito R
Brain Tumor Pathol; 2023 Apr; 40(2):48-55. PubMed ID: 36988764
[TBL] [Abstract][Full Text] [Related]
10. Adult IDH wild-type lower-grade gliomas should be further stratified.
Aibaidula A; Chan AK; Shi Z; Li Y; Zhang R; Yang R; Li KK; Chung NY; Yao Y; Zhou L; Wu J; Chen H; Ng HK
Neuro Oncol; 2017 Oct; 19(10):1327-1337. PubMed ID: 28575485
[TBL] [Abstract][Full Text] [Related]
11. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas.
Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T;
Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363
[TBL] [Abstract][Full Text] [Related]
12. Clinical, histopathological, and molecular analyses of IDH-wild-type WHO grade II-III gliomas to establish genetic predictors of poor prognosis.
Kuwahara K; Ohba S; Nakae S; Hattori N; Pareira ES; Yamada S; Sasaki H; Abe M; Hasegawa M; Hirose Y
Brain Tumor Pathol; 2019 Oct; 36(4):135-143. PubMed ID: 31324999
[TBL] [Abstract][Full Text] [Related]
13. The Place and Prognostic Value of TERT Promoter Mutation in Molecular Classification in Grade II-III Glial Tumors and Primary Glioblastomas.
Terzi NK; Yilmaz I; Oz AB
Turk Patoloji Derg; 2022; 38(2):90-98. PubMed ID: 34558656
[TBL] [Abstract][Full Text] [Related]
14. [Prognostic significance of combined TERT and IDH gene mutation analysis in diffusely infiltrating gliomas].
Liu QQ; Yin XX; Zou Y; Yu TP; Gong J; Chen XQ; Nie L; Xu M; Zhang MN; Zhou Q; Chen N
Zhonghua Bing Li Xue Za Zhi; 2018 Sep; 47(9):658-663. PubMed ID: 30220117
[No Abstract] [Full Text] [Related]
15. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
[TBL] [Abstract][Full Text] [Related]
16. Rapid progression of an IDH-wild type histological low-grade glioma harbouring TERT promoter mutation and diffuse CD34 expression: a case report.
Wang H; Tan C; Xu T; Li W
Folia Neuropathol; 2021; 59(1):104-111. PubMed ID: 33969682
[TBL] [Abstract][Full Text] [Related]
17. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
18. Telomerase Reverse Transcriptase Promoter Mutations in A Cohort Of Adult Gliomas - Clinicopathological Correlates.
Balakumar S; Pai R; Chacko AG; Patel B; Nancy R; Balakrishnan R; Sarkar S; Sampath G; Chacko G
Neurol India; 2022; 70(3):953-959. PubMed ID: 35864624
[TBL] [Abstract][Full Text] [Related]
19. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
[TBL] [Abstract][Full Text] [Related]
20. Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study.
Qiu X; Chen Y; Bao Z; Chen L; Jiang T
Radiother Oncol; 2022 Feb; 167():1-6. PubMed ID: 34902368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
